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SUMMARY
Cross-sectional study analyzed as case-control to identify risk factors for non-adherence to antiretroviral therapy. We studied 
412 out-clinics HIV infected subjects of three public hospitals of Recife, Pernambuco. The objective was to examine the association 
between non-adherence to the antiretroviral therapy and biological, social-behavior and demographics and economic factors, factors 
related to the disease and/or treatment, factors related to life habits and depression symptoms. Variables significantly associated with 
non-adherence to antiretroviral therapy were: time elapsed since HIV diagnosis (p = 0.002), daily dose (p = 0.046), use of alcohol 
(p = 0.030) and past drug use (p = 0.048), and borderline p-values were found for educational level (p = 0.093) and family monthly 
income (p = 0.08). In the multivariable analysis, the factors that remained in the final model were family monthly income, time period 
with HIV infection and use of alcohol. No association was observed between non-adherence to antiretroviral therapy and gender, age, 
sexual orientation, marital status, educational level and place of residence. 
Based on our results and the local situation we suggest: assessment of social needs; training of partners and/or families on 
supporting adherence, creation of “adherence groups” to motivate and to reassure patients on the benefits of treatment; counseling 
and/or psychotherapy for alcohol drinkers.
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INTRODUCTION
The use of combined antiretroviral agents starting in 1996, along 
with the routine use of primary prophylaxis for opportunistic infections, 
has had an important effect on the natural evolution of HIV disease, 
resulting in a reduction in complications from immune deficiency and 
an important reduction in morbidity and mortality27. This has given the 
disease the character of a chronic and potentially controllable illness. 
However, to achieve optimal viral suppression it is necessary a high level 
of adherence for an indefinite time period29. Consequently non-adherence 
to the proposed antiretroviral regimen is considered one of the greatest 
dangers to the response to treatment on an individual level and the 
dissemination of resistant viruses on the community level14.
Recent papers have described different methods for measuring 
adherence and discussed the advantages and disadvantages of each one 
but there is still no consensus concerning a gold standard26,30. Self-report 
measures of antiretroviral adherence can be robust, as they have been 
found to be associated with other indirect measures of adherence and 
viral load30. 
Adherence is the main factor health services act in order to enhance 
the effectiveness of the treatment as well as decrease the chance of the 
emergence of HIV resistance to antiretroviral drugs. For this reason, 
institutional and non-institutional guidelines have been produced22,26,34.
Non-adherence is multifactorial and several groups of variables have 
been implicated in its occurrence ranging from individual to health service 
and social factors2,4,15,24. 
The aim of the present study was to identify the main predictive 
factors regarding non-adherence to antiretroviral treatment among 
patients with HIV infection, with an emphasis on biological, social, 
behavioral, demographic, economic and psychological aspects. The 
understanding of such factors and their determinants is one of the main 
steps toward seeking new intervention strategies and thereby assuring 
therapeutic effectiveness. 
METHODOLOGY
The study involved male and female adult patients infected with HIV 
and in antiretroviral therapy for more than 15 days. All patients were 
in treatment from March to August 2001 and attending the out-patient 
clinics of one of the three reference hospitals for HIV/AIDS in the city 
of Recife: the Oswaldo Cruz University Hospital, the Correia Picanço 
Hospital and the Clinical Hospital in Recife, PE, Brazil. 
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A cross-sectional study was carried out and a case-control strategy 
was used in the analysis. HIV patients that reported having ingested less 
than 90% of the total number of the prescribed antiretroviral medication in 
the previous five days were considered as “cases” and those that reported 
having ingested 90% or more of the total number of the prescribed 
antiretroviral medication in the previous five days were considered as 
“controls”. The following variables were selected for the study: biological 
(gender, age); socio-behavioral and demographic (sexual behavior, 
marital status, level of education, city of residence); economic (work 
situation, monthly personal income and monthly family income); factors 
related to the disease and treatment (hospital attended, time elapsed since 
diagnosis, time elapsed since start of treatment, presence of symptoms, 
antiretroviral regimen in use, number of daily pills, expectation regarding 
treatment); factors related to living habits (use of alcohol, present or past 
drug use - marihuana, LSD, cocaine, heroin, ecstasy, crack and benzene 
derivates (participation in non-governmental organizations); and factors 
related to depression symptoms.
Data were collected using a questionnaire specially elaborated for the 
study through the Hamilton Scale13 for depression assessment, with a cut-
off point of 18 for the diagnosis of moderate to severe depression. Data 
were also obtained from the medical charts of patients who were unable 
to supply information as to the antiretroviral regimen being used.
To calculate the sample size, the frequency of exposure was based on 
two variables studied by GORDILLO et al 10. The sample size estimated 
was 352 patients for the mode of HIV transmission variable and 372 for 
the current work situation variable.
For the purpose of the analysis the variables were grouped in sets: 
biological, economic, factors related to disease and treatment, factors 
related to living habits and factors related to depression symptoms. The 
association of each variable with non-adherence was tested using the 
chi-square test, the odds ratio, the 95% confidence interval and p value; 
a p-value < 0.05 being considered statistically significant. Multivariate 
analysis was used to control the effect of each variable for the others. The 
model was first saturated with all variables whose association with death 
showed a p-value < 0.10 in the univariable analysis. Then the statistical 
significance of the removal of each variable from the model was tested, 
a p-value < 0.10 being the cut-off point considered.
From the identification of the variables whose association with 
non-adherence showed a p-value < 0.10 in the univariable analysis, a 
multivariable analysis was carried out in each set using multiple logistic 
regression. Finally, the variables which were retained in the final model 
in each set were adjusted for the effect of the others.
 The EPI-INFO (version 6.0)5 software program was used for 
calculating the sample size, as well as for the elaboration of the databank 
and the data analysis. For the logistic regression the SPSS-PC31 was 
used.
RESULTS
A total of 412 patients were studied, with a proportion of one case 
for every three controls; the frequency of non-adherence found was 
25.73%. The mean age of the patients was 36 years, ranging from 17 
to 67 years, and 69.2% of them were males. Concerning the level of 
education, approximately 51% of the patients had less than nine years 
of schooling, 7.3% of them being illiterate. Only 12% had university 
education. Around 62% of the patients had a family income ≤ 3 minimum 
wages and most of them lived in the Metropolitan Region of Recife. The 
majority (67%) had started treatment with HAART in the previous three 
years and 66% were symptomatic when the treatment was prescribed. 
Alcohol consumption was referred by 30% of the patients, past use of 
illicit drugs by 16.5% and present use by 6%.
The following variables showed a statistically significant association 
with non-adherence in the univariable analysis: time elapsed since the 
diagnosis of HIV infection (p = 0.002); larger number of daily pills (p 
= 0.046); use of alcohol (p = 0.03); and past drug use (p = 0.048). The 
variable “daily number of pills” had a statistically significant p-value (for 
all risk categories), but only those patients who used to take more than 
15 pills per day had a statistically significant 95% confidence interval 
for the odds ratio. A borderline association was observed with the 
following variables: level of education (p = 0.093) and monthly family 
income (p = 0.08). All variables for which the p-value of the association 
with non-adherence was equal to or less than 0.10 were introduced in a 
multivariate model in each set (socioeconomic, factors related to disease 
and treatment, factors related to living habits), - Tables 1, 2, 3 - and, 
subsequently, a final multivariate analysis was carried out with those 
selected in each group (Table 4). Monthly family income, time elapsed 
since diagnosis and use of alcohol remained in the final model, showing 
an independent association with non-adherence. 
DISCUSSION
Adherence to any type of health care is strongly recognized as a 
complex, multifaceted scientific issue. The lack of methodological 
standards makes assessments and comparisons between levels of 
Table 1
Odds ratio, confidence intervals and p-values for the association between 
socioeconomic factors and adherence to antiretroviral treatment, in patients 
attending the out-clinics of the reference hospitals for HIV treatment in Recife, 
from March to August 2001
Adherence in the previous 
five days
p-value Odds Ratio 95% IC
Level of Education p = 0.093
11 years of schooling 1 -
Eight years of schooling 0.86 0.37 - 2.03
Four years of schooling 1.35 0.61 - 3.04
Illiterate 2.24 0.74 - 6.82
Family Income  
(minimum wage)
p = 0.080
> 7 1 -
4 - 6 1.08 0.43 - 2.69
1 - 3 2.01 0.99 - 4.17
< 1 1.95 0.65 - 5.80
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cut-off point is associated with parameters of clinical and/or laboratorial 
improvement - as studies on HIV have suggested, less than excellent 
adherence may result in the emergence of resistant viruses3,21. The results 
of two randomized multicenter clinical trials conducted in the USA showed 
that adherence predicted nondetectable HIV RNA levels at 12 months of 
follow-up20. However newer data with NNRTI-based regimens (which also 
likely apply to ritonavir-boosted, PI-based regimens) suggest that current 
antiretroviral regimens can tolerate some degree of imperfect adherence 
while maintaining the beneficial effects of HIV therapy in most patients11. 
Thus the identification and development of antiretroviral combinations that 
show a high pharmacokinetic or genetic barrier to resistance are important 
in the long-term management of HIV19. 
Furthermore, other aspects are keys to the effectiveness of many 
components of antiretroviral treatment, such as the capacity of the 
patient in adhering to special instructions regarding dose intervals and 
dietary guidelines33.
In the present study, adequate adherence was considered to be the 
use of at least 90% of the prescribed medications10,17, taking into account 
the previous five days as a proxy of habitual behavior. The frequency 
of non-adherence was 25.73%, similar to the figure found in a study 
conducted in 60 outpatients services located in seven states of Brazil25. 
Other Brazilian studies reported figures from 17 to 48% of non-adherence 
and they explained that variation by the different ways adherence was 
Table 2 
Odds ratio, confidence intervals and p-values for the association between 
treatment related factors and adherence to antiretroviral treatment, in-patients 
attending the out-clinics of the reference hospitals for HIV treatment in Recife, 
from March to August 2001
Adherence in the  
previous five days
p-valueOdds Ratio 95% IC
Time elapsed since HIV 
diagnosis (years)
p = 0.002
< 1 1 -
1 - 3 4.03 1.82 - 9.14
4 - 5 2.43 0.99 - 6.06
6 - 10 2.72 1.14 - 6.59
> 10 1.14 0.11 - 6.32
Daily number of pills p = 0.046
1 - 4 1 -
5 -10 1.04 0.50 - 2.17
11 -15 1.11 0.49 - 2.54
> 15 2.54 1.03 - 6.35
Table 3
Odds ratio, confidence intervals and p-values for the association between  
habits and adherence to antiretroviral treatment, in patients attending  
the out-clinics of the reference hospitals for HIV treatment in Recife,  
from March to August 2001.
Adherence in the previous 5 days
p-valueOdds Ratio 95% IC
Use of alcohol p = 0.030
   No 1 -
   Yes 1.67 1.02 - 2.70 
Past use of drugs p = 0.048
   No 1 -
   Yes 1.75 1.00 - 3.03
Table 4
Adjusted odds ratio, confidence intervals and p-values for the association 
between socioeconomic and treatment related factors and habits with adherence 
to antiretroviral treatment, in patients attending the out-clinics of the reference 
hospitals for HIV treatment in Recife, from March to August 2001
 Adherence in the previous 5 days
Odds Ratio 95% IC p-value
Family income 
(minimum wage) *
p = 0.024
< 1 1 -
1 - 3 2.51 7.05 - 0.89
4 - 6 2.33 4.66 - 1.17
> 7 1.15 0.48 - 2.74
Time elapsed since  
diagnosis (years)
p = 0.045
< 1 1 -
1 - 3 3.90 8.70 - 1.74
4 - 5
6 - 10
2.63
3.23
6.51 - 1.06
7.70 - 1.35
> 10 1.10 5.85 - 0.20
Use of alcohol p = 0.095
No 1 -
Yes 1.56 0.93 - 2.53
* The family income was relative to the minimum wage (one minimum wage was 
approximately US$ 100.00).
adherence extremely difficult. As such, it is always necessary to consider 
the method used and the level at which adherence was defined. Several 
direct and indirect methods have been employed, but none can be 
considered the “gold standard”7. Despite being classically considered as 
methods that tend to overestimate adherence measures, when conducted 
well, those utilizing the direct questioning of the patients are adequate 
indicators of actual adherence. 
Another problem regards the level of adherence necessary for obtaining 
therapeutic effectiveness. Most studies on antiretroviral agents use a cut-off 
point of 80%, which is based on data from other chronic diseases, such 
as diabetes and hypertension6,18. With the HIV, which has an extremely 
high power of replication and mutation, there is no reassurance that this 
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conceptualized and measured and by a lack of definition of what should 
be considered optimal adherence12. BONOLO et al.2 review 43 articles 
on adherence to HAART. They found a mean rate of non-adherence 
of 30.4%, range from 5% to 67%. Interestingly, the rates reported in 
developing and developed countries were similar1.
Selection bias may have occurred, as only those patients who 
continued treatment were included in the study, whereas those who 
had abandoned treatment and no longer showed up to the medical 
consultations were left out. It is also possible that the patients who 
agreed to take part in the study were those who had better adherence. 
Moreover, as this study was based on facts that had already occurred 
and the information was obtained directly from the patients, there may 
have been failure in the use of medication which was not reported 
either because of memory lapse or for some other reason, leading to the 
misclassification of exposure. Non-differential misclassification, as it is 
likely to have occurred, may underestimate the measures of association. 
In an attempt to minimize some of these problems, data were collected 
from patients being treated at three reference hospitals in Recife, there 
was a great effort to avoid non-response and standard procedures and 
questionnaires were used. The number of patients studied per hospital 
was proportional to the number of patients registered and receiving 
antiretroviral therapy in each of these services. Cross-sectional studies 
are usually classified as descriptive but, in this case, the presence of 
appropriate comparison groups allows testing statistical association. 
However association refers to statistical dependence between two 
variables but it does not imply that the observed relationship is one of 
cause and effect. 
The association between socioeconomic condition and non-adherence 
is controversial, although divergences can be partly explained by the 
differences among the groups studied16,21,33. There is, however, an increasing 
inclination to consider socioeconomic condition (as assessed through 
income, level of education, job and housing conditions) as having a poor 
predictive power, except in cases of extreme poverty9,14. For instance, the 
study conducted in several Brazilian states found an association between 
a very low educational level and non-adherence25. It is possible that such 
socioeconomic factors are a proxy of other factors that could be the actual 
determinants of non-adherence, such as difficulty in obtaining adequate 
information on health and disease, difficult access to treatment centers, 
treatment costs and a lack of credibility in health centers32. It should be 
pointed out that most international studies are carried out in rich countries 
that have far more adequate systems of social support. 
In relation to the time elapsed since start of the antiretroviral 
treatment, it was not associated to non-adherence in this study. This 
differs from the literature, which states that in chronic diseases adherence 
usually declines over time8. However, it is necessary to keep in mind that 
most studies concerning length of treatment cover longer time periods, 
such as in the case of arterial hypertension, while the dissemination of 
antiretroviral therapy is relatively recent. The hypothesis that the average 
length of treatment was not long enough to demonstrate an effect on non-
adherence may be reinforced by the finding that a longer time elapsed 
since diagnosis of HIV implied a greater risk of non-adherence, even 
after adjustment for other variables. The increase in survival that has been 
observed in recent years may have produced a sense of “invulnerability” 
among the group of patients with a longer time since diagnosis, which 
may have contributed to low adherence. 
Despite the fact that the relation between alcohol and lower adherence 
is classic in the literature on tuberculosis8, its association with antiretroviral 
therapy has not been sufficiently studied. The relation between drug use 
and antiretroviral therapy is controversial. In the present study, in the 
analysis of the association between non-adherence and the use of drugs 
or alcohol, it was observed that both variables were associated with 
non-adherence in the univariate analysis, but the variable drug use lost 
the statistical significance in the multivariate model. It should be pointed 
out, however, that the frequency of patients that reported excessive use 
of alcohol or intravenous drugs was very low. Marijuana appeared as 
the principal illicit substance used. Studies on drug use and HIV focus 
mainly on intravenous drug users and it seems well established that such 
individuals exhibit higher rates of refusal to treatment28.
The Brazilian Ministry of Health proposed several strategies to be 
implemented in Health Units to increase adherence to antiretroviral 
treatment22. Integrated measures have been suggested: reduction of 
vulnerability and stigma, strengthen the participation of the users of health 
services increasing the dialogue with health professionals and a joint 
responsibility on the treatment23. In addition to global strategies, different 
sets of targeted interventions may be needed for special groups due to the 
wide spectrum of factors that may be related to non-adherence29. 
This study, by identifying risk factors for non-adherence in this 
setting, allows the early recognition of higher risk subgroups that should 
be carefully monitored along the antiretroviral treatment to increase its 
effectiveness. These subgroups could be identified with a screening for 
low monthly income, longer period elapsed since HIV diagnosis and 
alcohol drinkers. We suggest the following strategies, based on our 
results and the local situation: assessment of social needs; training of 
partners and/or families on supporting adherence, creation of “adherence 
groups” to motivate and to reassure patients on the benefits of treatment; 
counseling and/or psychotherapy for alcohol drinkers.
RESUMO
Fatores preditivos de não-adesão à terapia antiretroviral
Estudo transversal com análise tipo caso-controle, que avaliou 
412 pacientes de hospitais públicos do Recife - PE, com o objetivo 
de identificar fatores preditivos de não adesão à terapia antiretroviral. 
Verificou-se associação entre não adesão à terapia antiretroviral e 
aspectos biológicos, sócio-comportamentais e demográficos, econômicos, 
relacionados à doença e ao tratamento, aos hábitos de vida e aos distúrbios 
do humor. 
Variáveis com associação estatisticamente significante com não 
adesão na análise univariada foram: tempo de diagnóstico (p = 0,002), 
maior número diário de comprimidos (p = 0,046), uso de álcool (p = 
0,030) e uso de drogas no passado (p = 0,048). Observou-se associação 
limítrofe com grau de instrução (p = 0,093) e renda mensal familiar (p 
= 0,08). Após análise multivariada, permaneceram no modelo final: 
renda mensal familiar, tempo de diagnóstico e uso de álcool. Não 
houve associação entre gênero, idade, comportamento sexual, estado 
civil, grau de instrução, município de residência e não adesão à terapia 
antiretroviral.
Baseados nos nossos resultados e nas características da população 
estudada sugerimos: valorização das necessidades sociais, sensibilização 
de parceiros e/ou familiares para estimular a adesão, criação de grupos 
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de adesão para motivar e persuadir os pacientes sobre os benefícios do 
tratamento, aconselhamento e/ou psicoterapia para alcoolistas.
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